BioCentury
ARTICLE | Clinical News

Rozrolimupab: Final Phase II data

January 9, 2012 8:00 AM UTC

Final data from a dose-escalation, open-label, international Phase II trial in 61 Rhesus D (RhD)-positive, non-splenectomized patients with ITP showed that a single dose of 300 µg/kg IV Sym001 produce...